As prior studies reported that glucoregulatory agents such as metformin exhibited anticancer effects in a CD8 T cell-dependent manner [17], we next asked whether the enhanced tumor control we observed with ACA depended on an intact CD8 T cell response. The gene discussed is CD8A; the disease is neoplasm.